HPR253 Drug development and launch timeline analysis across 6 high-income countries: from pivotal trial to HTA
Zaitceva, V., Tan, I., Mills, M. & Kanavos, P.
(2024).
HPR253 Drug development and launch timeline analysis across 6 high-income countries: from pivotal trial to HTA.
Value in Health,
27(12, Supplement), S323 - S323.
https://doi.org/10.1016/j.jval.2024.10.1677
(2024).
HPR253 Drug development and launch timeline analysis across 6 high-income countries: from pivotal trial to HTA.
Value in Health,
27(12, Supplement), S323 - S323.
https://doi.org/10.1016/j.jval.2024.10.1677
This study aims to (1) investigate the time intervals between key steps in drug development and launch: pivotal clinical trial, regulatory approval, and HTA decision and (2) explore the impact of drug characteristics, clinical trial design, regulatory pathways, and firm characteristics on these timelines.